keyword
MENU ▼
Read by QxMD icon Read
search

Heart failure new treatments

keyword
https://www.readbyqxmd.com/read/28923249/akap-lbc-mediates-protection-against-doxorubicin-induced-cardiomyocyte-toxicity
#1
Stefania Caso, Darko Maric, Miroslav Arambasic, Susanna Cotecchia, Dario Diviani
Doxorubicin (DOX) is a chemotherapic agent that is widely used to treat hematological and solid tumors. Despite its efficacy, DOX displays significant cardiac toxicity associated with cardiomyocytes death and heart failure. Cardiac toxicity is mainly associated with the ability of DOX to alter mitochondrial function. The current lack of treatments to efficiently prevent DOX cardiotoxicity underscores the need of new therapeutic approaches. Our current findings show that stimulation of cardiomyocytes with the α1-adrenergic receptor (AR) agonist phenylephrine (PE) significantly inhibits the apoptotic effect of DOX...
September 16, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28903983/ivabradine-in-heart-failure-the-representativeness-of-shift-systolic-heart-failure-treatment-with-the-if-inhibitor-ivabradine-trial-in-a-broad-population-of-patients-with-chronic-heart-failure
#2
Debraj Das, Gianluigi Savarese, Ulf Dahlström, Michael Fu, Jonathan Howlett, Justin A Ezekowitz, Lars H Lund
BACKGROUND: The sinus node inhibitor ivabradine was approved for patients with heart failure (HF) after the ivabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial]) trial. Our objective was to characterize the proportion of patients with HF eligible for ivabradine and the representativeness of the SHIFT trial enrollees compared with those in the Swedish Heart Failure Registry. METHODS AND RESULTS: We examined 26 404 patients with clinical HF from the Swedish Heart Failure Registry and divided them into SHIFT type (left ventricular ejection fraction <40%, New York Heart Association class II-IV, sinus rhythm, and heart rate ≥70 beats per minute) and non-SHIFT type...
September 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28902721/hiv-associated-pulmonary-hypertension
#3
Harish Jarrett, Christopher Barnett
PURPOSE OF REVIEW: HIV-associated pulmonary arterial hypertension (HIV-PAH) is a well-recognized severe cardiovascular complication of HIV infection that confers an adverse prognosis irrespective of the stage of disease. This review will summarize the available data on HIV-PAH epidemiology and provide insights into the pathophysiology and therapeutic strategies currently available. RECENT FINDINGS: Patients with HIV are several thousand times more likely to develop HIV-PAH compared to the incidence of idiopathic PAH...
September 11, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28902412/interventions-for-treating-tuberculous-pericarditis
#4
REVIEW
Charles S Wiysonge, Mpiko Ntsekhe, Lehana Thabane, Jimmy Volmink, Dumisani Majombozi, Freedom Gumedze, Shaheen Pandie, Bongani M Mayosi
BACKGROUND: Tuberculous pericarditis can impair the heart's function and cause death; long term, it can cause the membrane to fibrose and constrict causing heart failure. In addition to antituberculous chemotherapy, treatments include corticosteroids, drainage, and surgery. OBJECTIVES: To assess the effects of treatments for tuberculous pericarditis. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register (27 March 2017); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27 March 2017); and LILACS (1982 to 27 March 2017)...
September 13, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28899229/thyroid-storm-a-japanese-perspective
#5
Takashi Akamizu
BACKGROUND: Thyroid storm (TS) is life threatening. In the mid-2000s, its incidence was poorly defined, peer-reviewed diagnostic criteria were not available, and management and treatment did not seem to be verified based upon evidence and latest advances in medicine. METHODS: We first developed diagnostic criteria based on 99 patients in the literature and our 7 patients. We then conducted initial and follow-up surveys from 2004 through 2008, targeting all hospitals in Japan to obtain and verify information on patients who met diagnostic criteria for TS...
September 13, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28898880/personalized-management-of-cardiovascular-disorders
#6
Kewal K Jain
Personalized management of cardiovascular disorders (CVDs), also referred to as personalized or precision cardiology in accordance with general principles of personalized medicine, is the selection of best treatment for an individual patient. It involves the integration of various 'omics' technologies such as genomics and proteomics as well as other new technologies such as nanobiotechnology. Molecular diagnostics and biomarkers are important for linking diagnosis with therapy and monitoring of therapy. Because CVDs involve perturbations of large complex biological networks, a systems biology approach to CVD risk stratification may be used for improving risk-estimating algorithms and modeling of personalized benefit-of-treatment may be helpful for guiding choice of intervention...
September 11, 2017: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
https://www.readbyqxmd.com/read/28895030/type-2-diabetes-and-cardiovascular-prevention-the-dogmas-disputed
#7
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito
In randomized controlled trials (RCTs), more intensive glucose control in patients with type 2 diabetes leads to a modest (9%) reduction in major cardiovascular events (MACE), associated with a 20% reduction of kidney events and 13% reduction of eye events. The FDA issued guidance in 2008 led to the conduct of numerous cardiovascular outcomes (CVOT) trials to assess cardiovascular safety of new antihyperglycemic therapies in patients with type 2 diabetes. The results of these trials show that insulin glargine, three different dipeptidyl peptidase-4 (DPP-4) inhibitors (saxagliptin, alogliptin, and sitagliptin) and lixisenatide (a glucagon like peptide-1 receptor agonist) produce no significant difference in CVOT when compared with usual care or placebo...
September 11, 2017: Endocrine
https://www.readbyqxmd.com/read/28893866/randomised-placebo-controlled-safety-and-tolerability-trial-of-fk506-tacrolimus-for-pulmonary-arterial-hypertension
#8
Edda Spiekerkoetter, Yon K Sung, Deepti Sudheendra, Valerie Scott, Patricia Del Rosario, Matthew Bill, Francois Haddad, Janel Long-Boyle, Haley Hedlin, Roham T Zamanian
Pulmonary arterial hypertension (PAH) is a devastating disease characterised by occlusive pulmonary vasculopathy. Activation of bone morphogenetic protein receptor 2 (BMPR2) signalling by FK506 (tacrolimus) reverses occlusive vasculopathy in rodent PAH models. Here, we determined the safety and tolerability of low-level FK506 therapy in stable PAH patients.We performed a randomised, double-blind, placebo-controlled, 16-week, single-centre, phase IIa trial in PAH patients with New York Heart Association functional class II/III symptoms using three FK506 target levels (<2, 2-3 and 3-5 ng·mL(-1))...
September 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28891228/investigating-a-biomarker-driven-approach-to-target-collagen-turnover-in-diabetic-heart-failure-with-preserved-ejection-fraction-patients-effect-of-torasemide-vs-furosemide-on-serum-c-terminal-propeptide-of-procollagen-type-i-drop-pip-trial
#9
Tobias Daniel Trippel, Sophie Van Linthout, Dirk Westermann, Ruhdja Lindhorst, Anja Sandek, Stefanie Ernst, Anna Bobenko, Mario Kasner, Frank Spillmann, Arantxa González, Begoña López, Susana Ravassa, Burkert Pieske, Walter J Paulus, Javier Díez, Frank Edelmann, Carsten Tschöpe
AIM: Heart failure with preserved ejection fraction (HFpEF) is associated with myocardial remodelling including severe pro-fibrotic changes contributing to an increase in left ventricular stiffness and diastolic dysfunction. Serum C-terminal propeptide of procollagen type I (PIP) strongly correlates with the turnover of extracellular cardiac matrix proteins and fibrosis. Torasemide, but not furosemide, was described to reduce collagen type I synthesis in clinically unstable patients with heart failure with reduced ejection fraction...
September 11, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28890834/the-use-of-a-novel-heart-failure-agent-in-the-treatment-of-pregnancy-associated-cardiomyopathy
#10
Vamsi C Gaddipati, Aarti A Patel, Adam J Cohen
Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy...
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28888522/sleep-disordered-breathing-and-heart-failure-what-does-the-future-hold
#11
REVIEW
Martin R Cowie, Angela M Gallagher
Most patients with heart failure (HF) have sleep-disordered breathing (SDB), with central (rather than obstructive) sleep apnea becoming the predominant form in patients with more severe disease. Cyclical apnea and hypopneas are associated with sleep disturbance, hypoxemia, hemodynamic changes, and sympathetic activation. These patients have a worse prognosis than those without SDB. Mask-based therapies of positive airway pressure targeted at SDB can improve measures of sleep quality and can partially normalize the sleep and respiratory physiology...
August 30, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28887110/percutaneous-decommissioning-of-left-ventricular-assist-device
#12
Jia-Lin Soon, Ju-Le Tan, Choon-Pin Lim, Teing-Ee Tan, Swee-Yaw Tan, Ka-Lee Kerk, Kheng-Leng David Sim, Cumaraswamy Sivathasan
BACKGROUND: The Left Ventricular Assist Device (LVAD) has revolutionised our treatment of advanced stage heart failure, giving debilitated patients a new lease on life. A small proportion of these LVAD patients can be bridged-to-recovery. The identification of these patients and decision to wean, however, can be challenging. METHODS: The need to fully explant the device upon recovery has evolved to a minimalist approach aiming to avoid injury to the 'recovered' heart...
August 19, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28887060/ethnicity-in-pulmonary-arterial-hypertension-possibilities-for-novel-phenotypes-in-the-age-of-personalized-medicine
#13
Sarah K Medrek, Sandeep Sahay
In the last decade and a half, the introduction of new therapeutics has revolutionized the management of pulmonary arterial hypertension (PAH). These new treatment options have improved the quality of life and survival in PAH. With an armamentarium of options available, the identification of unique phenotypes can help practitioners choose tailored treatment regimens. Experts in other cardiovascular diseases such as congestive heart failure and hypertension have recommended race-specific treatments in their fields based on data highlighting variations in response to therapies...
September 5, 2017: Chest
https://www.readbyqxmd.com/read/28882229/care-patterns-and-outcomes-in-atrial%C3%A2-fibrillation-patients-with-and-without-diabetes-orbit-af-registry
#14
MULTICENTER STUDY
Justin B Echouffo-Tcheugui, Peter Shrader, Laine Thomas, Bernard J Gersh, Peter R Kowey, Kenneth W Mahaffey, Daniel E Singer, Elaine M Hylek, Alan S Go, Eric D Peterson, Jonathan P Piccini, Gregg C Fonarow
BACKGROUND: Diabetes is a well-established risk factor for thromboembolism in patients with atrial fibrillation (AF), but less is known about how diabetes influences outcomes among AF patients. OBJECTIVES: This study assessed whether symptoms, health status, care, and outcomes differ between AF patients with and without diabetes. METHODS: The cohort study included 9,749 patients from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry, a prospective, nationwide, outpatient registry of patients with incident and prevalent AF...
September 12, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28879633/the-initial-evaluation-and-management-of-a-patient-with-heart-failure
#15
REVIEW
Jamael Hoosain, Jabar Whittier, Farhan Hasni, Shelley Hankins
PURPOSE OF REVIEW: The goal of this review is to summarize and discuss a thorough and effective manner in the evaluation of the patient with heart failure. RECENT FINDINGS: Heart failure is a prevalent disease worldwide and while the diagnosis of heart failure has remained relatively unchanged via a careful history and physical examination, identification of the etiology of the heart failure and treatment has made significant advances. Mechanical circulatory support (MCS), neprilysin inhibitors, and chronic resynchronization therapy (CRT) are just some of the relatively recent therapies afforded to assist heart failure patients...
September 6, 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28877714/successful-medical-management-of-a-case-of-austrian-syndrome-an-uncommon-entity-in-the-modern-antibiotic-era-a-case-report
#16
Muhammad Abdur Rahim, Shahana Zaman, Hasna Fahmima Haque, Samira Rahat Afroze, Khwaja Nazim Uddin
BACKGROUND: Austrian syndrome-the combination of meningitis, pneumonia and infective endocarditis due to Streptococcus pneumoniae infection, is a rare entity. In literature only a few hundreds of cases are reported but surprisingly we did not find any report on Austrian syndrome in or from Bangladesh. CASE PRESENTATION: We report the case history of a middle aged Bangladeshi diabetic man, who had fever, cough, shortness of breath and altered mentation. He had tachycardia, bi-basal lung crepitations, new cardiac murmurs and meningism...
September 6, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28877121/begin-again-and-continue-with-life-a-qualitative-study-on-the-experiences-of-cardiac-rehabilitation-patients
#17
Fariba Jokar, Hojatllah Yousefi, Alireza Yousefy, Masoumeh Sadeghi
BACKGROUND: Cardiovascular diseases are a main cause of mortality worldwide. However, new diagnostic techniques and treatments have increased the rate of survival for patients with cardiovascular disease. Cardiac rehabilitation programs aim to maintain and enhance the quality of life of patients and improve the secondary prevention of coronary artery disease. Suboptimal participation in rehabilitation programs, early exit from these programs, and not achieving lasting changes are cardiac rehabilitation challenges that are associated with health issues, including the increased need for medication, repeated hospitalization, failure in the secondary prevention programs, and long waiting lists...
October 2017: Journal of Nursing Research: JNR
https://www.readbyqxmd.com/read/28875984/multiscale-technologies-for-treatment-of-ischemic-cardiomyopathy
#18
REVIEW
Morteza Mahmoudi, Mikyung Yu, Vahid Serpooshan, Joseph C Wu, Robert Langer, Richard T Lee, Jeffrey M Karp, Omid C Farokhzad
The adult mammalian heart possesses only limited capacity for innate regeneration and the response to severe injury is dominated by the formation of scar tissue. Current therapy to replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer progressive decay in the heart's pumping capacity to the point of heart failure. Nanostructured systems have the potential to revolutionize both preventive and therapeutic approaches for treating cardiovascular disease. Here, we outline recent advancements in nanotechnology that could be exploited to overcome the major obstacles in the prevention of and therapy for heart disease...
September 6, 2017: Nature Nanotechnology
https://www.readbyqxmd.com/read/28874462/%C3%AE-arrestin2-improves-post-myocardial-infarction-heart-failure-via-sarco-endo-plasmic-reticulum-ca-2-atpase-dependent-positive-inotropy-in-cardiomyocytes
#19
Katie A McCrink, Jennifer Maning, Angela Vu, Malika Jafferjee, Christine Marrero, Ava Brill, Ashley Bathgate-Siryk, Samalia Dabul, Walter J Koch, Anastasios Lymperopoulos
Heart failure is the leading cause of death in the Western world, and new and innovative treatments are needed. The GPCR (G protein-coupled receptor) adapter proteins βarr (β-arrestin)-1 and βarr-2 are functionally distinct in the heart. βarr1 is cardiotoxic, decreasing contractility by opposing β1AR (adrenergic receptor) signaling and promoting apoptosis/inflammation post-myocardial infarction (MI). Conversely, βarr2 inhibits apoptosis/inflammation post-MI but its effects on cardiac function are not well understood...
September 5, 2017: Hypertension
https://www.readbyqxmd.com/read/28873219/treatment-effectiveness-in-heart-failure-with-comorbidity-lung-disease-and-kidney-disease
#20
Jerry H Gurwitz, David J Magid, David H Smith, Grace H Tabada, Sue Hee Sung, Larry A Allen, David D McManus, Robert J Goldberg, Mayra Tisminetzky, Alan S Go
OBJECTIVES: To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease. DESIGN: Retrospective cohort study. SETTING: Community. PARTICIPANTS: Individuals with HF with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF)...
September 5, 2017: Journal of the American Geriatrics Society
keyword
keyword
90300
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"